Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Non-Small-Cell Lung 2Neoplasms, Second Primary 1Leukemia, Myeloid, Chronic-Phase 1Gastro Intestinal Stromal Tumor 1Congenital Abnormalities 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Sunitinib 17Sorafenib 16pazopanib 7cabozantinib 7Axitinib 7Blood Specimen Collection 6Bevacizumab 6avelumab 5Immunohistochemistry 5temsirolimus 4pembrolizumab 3Watchful Waiting 3Specimen Handling 3Immunotherapy 3Gene Expression Profiling 3Everolimus 3Urine Specimen Collection 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Flow Cytometry 2Data Collection 2Amplified Fragment Length Polymorphism Analysis 2trastuzumab deruxtecan 1lenvatinib 1fluoroazomycin arabinoside 1enfortumab vedotin 1darolutamide 1atezolizumab 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Carcinoma, Renal Cell × Tyrosine Kinase Inhibitors × Clear all
NCT04375150 2024-09-19

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Pfizer

Completed
355 enrolled 23 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡